Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs

American Journal of Veterinary Research

Volumn 77, Issue 1, 2016, Pages 65-71

  Larson, Jeanne C ^a   Allstadt, Sara D ^a   Fan, Timothy M ^b   Khanna, Chand ^c   Lunghofer, Paul J ^d   Hansen, Ryan J ^d   Gustafson, Daniel L PHD ^d   Legendre, Alfred M ^a   Galyon, Gina D ^a   LeBlanc, Amy K ^a,c   Martin Jimenez, Tomas ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

AREA UNDER THE CURVE; ARTICLE; DOG; DRUG HALF LIFE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BLOOD; CLINICAL TRIAL; HALF LIFE TIME; LIQUID CHROMATOGRAPHY; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DOGS; HALF-LIFE; SIROLIMUS;

EID: 84952333992     PISSN: 00029645     EISSN: 19435681     Source Type: Journal    
DOI: 10.2460/ajvr.77.1.65     Document Type: Article

References (26)

1. Baker H, Sidorowicz A, Sehgal SN, et al. Rapamycin (AY-22, 989), a new antifungal antibiotic III. In vitro and in vivo evaluation. J Antibiot (Tokyo) 1978;31:539-545.
2. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003;2:222-232.
3. Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005;14:313-328.
4. Guba M, Von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-135.
5. Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des 2012;18:2766-2777.
6. Beck JT, Ismail A, Tolomeo C. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Cancer Treat Rev 2014;40:980-989.
7. Fumarola C, Bonelli MA, Petronini PG, et al. Targeting PI3K/ AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol 2014;90:197-207.
8. Martin-Liberal J, Gil-Martin M, Sáinz-Jaspeado M, et al. Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours. Br J Cancer 2014;111:858-865.
9. Gordon IK, Ye F, Kent MS. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs. Am J Vet Res 2008;69:1079-1084.
10. Murai A, Asa SA, Kodama A, et al. Immunohistochemical analysis of the Akt/mTOR/4E-BP1 signaling pathway in canine hemangiomas and hemangiosarcomas. J Comp Pathol 2012;147:430-440.
11. Murai A, Asa SA, Kodama A, et al. Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines. BMC Vet Res [serial online] 2012;8:128. Available at: www.biomedcentral.com/1746-6148/8/128. Accessed January 23, 2015.
12. Kent MS, Collins CJ, Ye F. Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines. Am J Vet Res 2009;70:263-269.
13. Collier DS, Calne R, Thiru S, et al. Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc 1990;22:1674-1675.
14. Knight R, Ferraresso M, Serino F, et al. Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 1993;55:947-949.
15. Hartner WC, Van der Werf WJ, Lodge PA, et al. Effect of rapamycin on renal allograft survival in canine recipients treated with antilymphocyte serum, donor bone marrow, and cyclosporine. Transplantation 1995;60:1347-1350.
16. Yi H, Brooks ED, Thurberg BL. Correction of glycogen storage disease type III with rapamycin in a canine model. J Mol Med 2014;92:641-650.
17. Paoloni MC, Mazcko C, Fox E, et al. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS ONE [serial online] 2010;5:e11013. Available at: journals.plos.org/plosone/ article?id=10.1371/journal.pone.0011013. Accessed January 23, 2015.
18. Clavijo C, Strom T, Moll V, et al. Development and validation of a semi-automated assay for the highly sensitive quantification of Biolumus A9 in human whole blood using high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:3506-3514.
19. Deters M, Kirchner G, Resch K, et al. Simultaneous quantification of sirolimus, everolimus, tacrolimus, and cyclosporine by liquid chromatography-mass spectrometry (LC-MS). Clin Chem Lab Med 2002;40:285-292.
20. Bansel S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J 2007;9:E109-E114.
21. Lampen A, Zhang Y, Hackbarth I, et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 1998;285:1104-1112.
22. Davis NM, Takemoto JK, Brocks DR, et al. Multiple peaking phenomena in pharmacokinetic disposition. Clin Pharmacokinet 2010;49:351-377.
23. Guba M, Koehl GE, Neppl E, et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 2005;18:89-94.
24. Salm P, Tresillian MJ, Taylor PJ, et al. Stability of sirolimus (rapamycin) in whole blood. Ther Drug Monit 2000;22:423-426.
25. Capone D, Gentile A, Polichetti G, et al. Stability of sirolimus and everolimus measured by immunoassay techniques in whole blood samples from kidney transplant patients. Int J Immunopathol Pharmacol 2008;21:297-307.
26. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000;14:97-109.